147 related articles for article (PubMed ID: 31245606)
21. The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study.
McTaggart-Cowan H; King MT; Norman R; Costa DSJ; Pickard AS; Viney R; Peacock SJ;
Health Qual Life Outcomes; 2022 Jun; 20(1):97. PubMed ID: 35710417
[TBL] [Abstract][Full Text] [Related]
22. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
[TBL] [Abstract][Full Text] [Related]
23. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H; Cook G; Goodall S; Liew D
Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
[TBL] [Abstract][Full Text] [Related]
24. Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment.
Norman R; Kemmler G; Viney R; Pickard AS; Gamper E; Holzner B; Nerich V; King M
Value Health; 2016 Dec; 19(8):1033-1038. PubMed ID: 27987630
[TBL] [Abstract][Full Text] [Related]
25. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
[TBL] [Abstract][Full Text] [Related]
26. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
Klapproth CP; Fischer F; Rose M; Karsten MM
J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
[TBL] [Abstract][Full Text] [Related]
27. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
[TBL] [Abstract][Full Text] [Related]
28. Erratum to: QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.
King MT; Costa DSJ; Aaronson NK; Brazier JE; Cella DF; Fayers PM; Grimison P; Janda M; Kemmler G; Norman R; Pickard AS; Rowen D; Velikova G; Young TA; Viney R
Qual Life Res; 2016 Oct; 25(10):2683. PubMed ID: 27060088
[No Abstract] [Full Text] [Related]
29. Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.
Bulamu NB; Chen G; Ratcliffe J; Schloite A; Bright T; Watson DI
World J Surg; 2019 Jun; 43(6):1554-1562. PubMed ID: 30719557
[TBL] [Abstract][Full Text] [Related]
30. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
[TBL] [Abstract][Full Text] [Related]
31. Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain.
Fredheim OM; Borchgrevink PC; Saltnes T; Kaasa S
J Pain Symptom Manage; 2007 Dec; 34(6):657-65. PubMed ID: 17618079
[TBL] [Abstract][Full Text] [Related]
32. United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument.
King MT; Revicki DA; Norman R; Müller F; Viney RC; Pickard AS; Cella D; Shaw JW;
Pharmacoecon Open; 2024 Jan; 8(1):49-63. PubMed ID: 38060096
[TBL] [Abstract][Full Text] [Related]
33. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
34. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
35. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain.
Giesinger JM; Kuijpers W; Young T; Tomaszewski KA; Friend E; Zabernigg A; Holzner B; Aaronson NK
Health Qual Life Outcomes; 2016 Jun; 14():87. PubMed ID: 27267486
[TBL] [Abstract][Full Text] [Related]
36. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
37. The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set.
King MT; Norman R; Mercieca-Bebber R; Costa DSJ; McTaggart-Cowan H; Peacock S; Janda M; Müller F; Viney R; Pickard AS; Cella D;
Value Health; 2021 Jun; 24(6):862-873. PubMed ID: 34119085
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
39. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.
Li Q; Lin Y; Qiu Y; Gao B; Xu Y
Eur J Oncol Nurs; 2014 Aug; 18(4):425-35. PubMed ID: 24721179
[TBL] [Abstract][Full Text] [Related]
40. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
